Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
Hims & Hers faces scrutiny from senators on Super Bowl ad that 'risks misleading' patients
Doximity shares pop 36% on revenue beat, rosy guidance
Alphabet's Verily to sell Granular insurance business to Elevance Health
Doximity shares soar 25% after company beats on revenue, raises fiscal-year guidance
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Bristol Myers' stock decline in response to weak guidance is a gift to investors
